Dazonone

CAS No. 105622-85-3

Dazonone( Imidazo[2,1-b]quinazolin-2(3H)-one, 6-chloro-1,5-dihydro-3-methyl- )

Catalog No. M28942 CAS No. 105622-85-3

Dazonone is a specific PDE III inhibitors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 133 In Stock
5MG 153 In Stock
10MG 225 In Stock
25MG 337 In Stock
50MG 465 In Stock
100MG 625 In Stock
200MG 828 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dazonone
  • Note
    Research use only, not for human use.
  • Brief Description
    Dazonone is a specific PDE III inhibitors.
  • Description
    Dazonone is a specific PDE III inhibitors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Imidazo[2,1-b]quinazolin-2(3H)-one, 6-chloro-1,5-dihydro-3-methyl-
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    105622-85-3
  • Formula Weight
    235.67
  • Molecular Formula
    C11H10ClN3O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1N=C2NC=3C=CC=C(Cl)C3CN2C1C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.K Hoya, et al. A Novel Intravascular Drug Delivery Method Using Endothelial Biotinylation and Avidin-Biotin Binding. Drug Deliv. Oct-Dec 2001;8(4):215-22.
molnova catalog
related products
  • Enoximone

    Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.

  • Imazodan

    Imazodan, a small molecule compound with positive inotropic activity, is a selective type III phosphodiesterase inhibitor and can be used to study heart failure.

  • Ensifentrine

    Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.